This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.

开始日期2026-07-07

申办/合作机构

National Cancer Institute

NCT07394946

/ Not yet recruiting临床2期IIT

Neo-Adjuvant Endocrine Therapy in Post-Menopausal Hormone Receptor Positive HER 2 Neu Negative Node Positive Early-Stage Breast Cancer Patients With One Year of Letrozole.

The goal of this clinical trial is to learn whether letrozole, a hormone therapy drug, is effective in treating early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to nearby lymph nodes in postmenopausal women. The study will also evaluate the safety of taking letrozole for one year before surgery.
The main questions this study aims to answer are:
Can one year of letrozole eliminate cancer from the underarm (axillary) lymph nodes?
Can treatment with letrozole reduce the need for extensive lymph node surgery?
How safe and tolerable is long-term letrozole treatment?
This is a single-arm study, meaning all participants will receive letrozole. There is no placebo or comparison group.
Participants will:
Take letrozole 2.5 mg by mouth once daily for one year
Attend regular clinic visits for physical exams, blood tests, and imaging studies
Undergo surgery after completing treatment
Be followed for up to two years to monitor cancer recurrence and survival

开始日期2026-06-01

申办/合作机构-

NCT07492641

/ Not yet recruiting临床3期

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.

开始日期2026-05-11

申办/合作机构

BeOne Medicines Ltd.

100 项与来曲唑相关的临床结果

登录后查看更多信息

100 项与来曲唑相关的转化医学

登录后查看更多信息

100 项与来曲唑相关的专利（医药）

登录后查看更多信息

5,035

项与来曲唑相关的文献（医药）

2026-05-01·CANCER LETTERS

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial

Article

作者: Ying, Jianming ; Ma, Fei ; Fan, Ying ; Tan, Yujing ; Luo, Yang ; Xue, Xuemin ; Wang, Bingzhi ; Chen, Shanshan ; Lan, Bo ; Wang, Jiayu ; Xu, Binghe ; Ji, Danyang ; Xue, Liyan

Breast cancer is the most commonly diagnosed cancer in women globally. Our previous MIRACLE trial (NCT02313051) demonstrated that everolimus plus letrozole (E + L) significantly improves progression-free survival compared with letrozole (L) monotherapy in premenopausal patients with endocrine therapy-resistant, hormone receptor-positive, HER2-non-amplified advanced breast cancer. This study aims to investigate spatially resolved biomarkers linked to survival benefits from E + L to guide precision therapies. Patients from MIRACLE were stratified by overall survival (OS ≤ 3 vs. >3 years). Spatial Whole Transcriptome Atlas analysis was used to evaluate tumor-, immune-, and stroma-specific gene expression, co-expression network patterns, and survival correlations. Among patients with shorter survival (OS ≤ 3 years), we identified a distinctive gene interaction network characterized by tumor-derived S100A9 and CALML5, which is associated with mTORC1 activation. This finding suggests that tasquinimod, an S100A9 inhibitor, could be a viable therapeutic option. Additionally, an interaction between CALML5 and SLPI across tumor and immune areas indicated a potential role in maintaining tumor integrity and mitigating immune-mediated damage. Conversely, patients with longer survival (OS > 3 years) exhibited SERPINA1 as a hub gene linked to estrogen receptor activation, and an interaction between FKBP5 and SESN3 associated with AKT/mTORC1 inhibition within tumor-rich regions. Furthermore, the interaction between MMP11 and COL16A1 in stroma-rich regions suggests that cancer-associated fibroblasts may contribute to improved outcomes. Our study underscores the critical role of spatial gene expression analysis in elucidating the tumor microenvironment and its impact on prognosis in patients undergoing E + L treatment, thereby opening new avenues for targeted interventions.

2026-05-01·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Polycystic ovarian syndrome - Exploring the therapeutic and biomedical insights into the role of silver nanoparticles

Review

作者: Shanmugam, Rajeshkumar ; Baskar, Gomathy ; Muthukumaran, Dhanyaa ; Anitha, V

A prevalent endocrinopathy affecting reproductive-age women is polycystic ovarian syndrome (PCOS), which affects around 5-20 % of these individuals. PCOS is closely linked to the following causes: immunological, endocrine, and reactive oxygen species (ROS). Plant extracts are used in the synthesis of silver nanoparticles (AgNPs), which are employed for PCOS treatment. Ag NPs can regulate the hormonal imbalance, reducing pro-inflammatory cytokines and ovarian cysts in PCOS. Conventional medicines, such as metformin, clomiphene citrate, letrozole, flutamide, and rosiglitazone, can regulate menstrual irregularities, improve ovulation, reduce insulin resistance, and decrease androgen levels, but may also cause various side effects. As a result, AgNPs are more effective at optimized doses in the short term used in the treatment of PCOS. The present article provides an uncommon overview of the mechanism of action and safety of AgNPs that are biosynthesized to treat the PCOS condition. The review includes evidence from insulin, inflammation, oxidative processes, neuroendocrine factors and cystogenic pathways to combine and provide an overview. The review also discusses how to approach toxicity, especially dose-dependent, and the reproductive safety of AgNPs and their translational limitations to define the boundaries of AgNPs in the treatment of PCOS.

2026-05-01·STEROIDS

Kaempferol ameliorates PCOS by alleviating metabolic and endocrine abnormalities as well as oxidative stress

Article

作者: Roshangar, Leila ; Nejabati, Hamid Reza

Polycystic ovary syndrome (PCOS) is an endocrine irregularity aligned with enhanced androgen levels, insulin resistance (IR), dyslipidemia, ovulation disorders, and infertility. For decades, natural active ingredients from plants have been utilized as pharmaceuticals to treat a wide range of reproductive system disorders. Most importantly, their effects are achieved either through targeting enzymes, hormones, and/or eliminating reactive oxygen species (ROS) in ovarian cells. Kaempferol (KPF) is a natural flavonol belonging to the flavonoid family and has various medicinal features like anti-inflammatory, antioxidative, anticancer, antimicrobial, and cardioprotective properties. Recently, studies have investigated the medicinal impact of various plant extracts containing high concentrations of KPF in animal models of PCOS. The results of these studies show that this flavonol can boost the metabolic and hormonal abnormalities of rat with PCOS. In this research paper, for the first time, the molecular effects of KPF on improving metabolic and hormonal as well as oxidative stress parameters of PCOS rats were investigated. In this study, 30 Sprague-Dawley rats were arbitrarily studied in four groups: control, letrozole-induced PCOS, KPF, KPF+ metformin (MET). The blood species, adipose and ovarian tissues were prepared to investigate the therapeutic impacts of KPF on PCOS rats. Our results pointed out that the examined therapeutic factors effectively alleviated HA, IR as well as oxidative stress in PCOS rats and improved the browning of adipose tissue in these animals. To the best of our knowledge, this report is the first that indicates the favorable effects of KPF on steroidogenesis, insulin resistance and oxidative stress-related genes in rats with PCOS. Our findings showed that it successfully regulates the mentioned abnormalities in generated animal model. Therefore, these data point out that KPF can be a novel medicinal alternative for women with PCOS.

774

项与来曲唑相关的新闻（医药）

2026-04-01

·ioncology

BC TALK丨陈文艳教授：从PATINA研究看HR+/HER2+晚期乳腺癌一线维持治疗新策略——CDK4/6抑制剂的联合价值

点击上方蓝字关注我们引言：激素受体阳性（HR+）/人表皮生长因子受体2阳性（HER2+）乳腺癌占所有乳腺癌的10.3%[1]。我国一项对32056例HER2阳性早期乳腺癌的统计显示，HR阳性在其中占比高达50.8%，是临床治疗中相对棘手的一种亚型[2]。既往HR+/HER2+晚期乳腺癌的一线治疗策略多为曲妥珠单抗（H）+帕妥珠单抗（P）+化疗诱导治疗后，序贯抗HER2靶向治疗联合内分泌治疗（ET）维持[3,4]。然而，由于HR与HER2信号通路之间存在相互作用，单纯靶向其中任一通路均可能导致耐药，对细胞周期蛋白依赖性激酶4/6（CDK4/6）及HER2的双重抑制可能是解决这一问题的有效策略。 2017年6月，覆盖8个国家123个研究中心的III期PATINA研究正式启动。该研究主要纳入HR+/HER2+晚期乳腺癌一线治疗患者，旨在评估在4~8个周期抗HER2靶向治疗联合化疗后，以CDK4/6抑制剂哌柏西利联合抗HER2靶向治疗及ET治疗作为维持治疗方案的疗效。2024年10月，该研究基本完成，随后多项研究结果陆续公布。 2024年圣安东尼奥乳腺癌研讨会（SABCS）披露了该研究无进展生存期（PFS）、客观缓解率（ORR）及安全性的初步分析结果，初步证实了该策略的有效性[5]。 2025年欧洲肿瘤内科学会（ESMO）年会公布了该研究健康相关生活质量（HRQOL）结果，提示在抗HER2靶向治疗联合ET治疗的维持方案中加用CDK4/6抑制剂未对患者生活质量造成显著影响[6]。 2026年《新英格兰医学杂志》（《NEJM》）正式刊发了该研究的疗效及安全性结果，为国内外临床治疗格局的更新提供了关键循证依据[7]。面对PATINA研究所带来的治疗格局变革，临床实践中应如何理解、如何应对？本期BC TALK特邀南昌市人民医院陈文艳教授予以深入解读，与读者分享。从基础到临床 PATINA研究启动一线维持治疗联合CDK4/6抑制剂的探索 HR+/HER2+乳腺癌是临床中具有独特生物学行为的乳腺癌亚型，HR与HER2信号通路之间存在串扰，单纯ET治疗或抗HER2治疗均难以持久奏效[8]。基础研究显示，CDK4/6和HER2的激活均会促进下游TSC2磷酸化，进而解除TSC2对mTORC1的抑制，推动细胞进入S期。CDK4/6抑制剂与抗HER2靶向治疗均可阻断TSC2-mTORC1的信号轴，加之CDK4/6抑制剂对RB的直接抑制作用，可进一步增强细胞阻滞效果，发挥协同抗肿瘤作用[9]。 CDK4/6抑制剂与抗HER2靶向治疗的协同机制在该机制的指导下，NA-PHER2研究[10]、SOLTI-1303 PATRICIA研究[11]、TOUCH研究[12]等早期探索已初步验证了CDK4/6抑制剂联合抗HER2靶向治疗在HR+/HER2+乳腺癌中的可行性。然而，在HR+/HER2+晚期乳腺癌的一线治疗中，诱导治疗后的维持阶段既往多采用抗HER2靶向联合内分泌治疗的策略，尚缺乏联合CDK4/6抑制剂的高级别循证医学证据。 PATINA研究是首个在HR+/HER2+晚期乳腺癌一线维持治疗中，比较标准治疗方案联合与不联合CDK4/6抑制剂哌柏西利的疗效及安全性的III期研究。这项国际多中心、随机对照的III期研究共纳入518例患者，入组条件为接受4~8个周期化疗联合HER2靶向治疗后未出现疾病进展。患者按1:1随机分为两组：对照组接受H±P联合ET治疗的基础维持方案，试验组在对照组基础上加用CDK4/6抑制剂哌柏西利。ET治疗包括芳香化酶抑制剂（AI）或氟维司群，绝经前患者要求接受卵巢功能抑制。主要研究终点为无进展生存期（PFS），次要研究终点包括客观缓解率（ORR）、总生存期（OS）及安全性等。 PATINA研究设计疗效提升 HR+/HER2+乳腺癌一线治疗新突破近期，《NEJM》全文刊发了该研究的阳性结果。入组的518例患者中，接受H±P治疗、选择AI的患者比例均超过90%。治疗结束时，哌柏西利联合H±P+ET组与H±P+ET组分别有28.7%、21.8%的患者仍在接受治疗。中位随访53.3个月时，哌柏西利联合H±P+ET组较H±P+ET组显著延长了mPFS（44.3个月 vs 29.1个月），疾病进展或死亡风险降低了25%（HR=0.75；95%CI，0.59-0.96；双侧未分层P=0.02，分层P=0.03）。两组5年PFS率分别为43.2%和33.4%。亚组分析显示，哌柏西利联合H±P+ET组在各亚组中均呈现获益趋势，其中AI治疗组相比氟维司群组、无内脏转移组相比内脏转移组、绝经前组相比绝经后组、ER+/PR-组相比ER+/PR+组的获益趋势更为显著。 PATINA研究PFS结果及亚组分析在肿瘤缓解方面，哌柏西利联合H±P+ET组相较对照组在客观缓解率（32.9% vs 24.8%）和完全缓解率（14.3% vs 11.3%）方面均呈现优势，提示联合治疗在肿瘤缓解方面更具优势。 PATINA研究肿瘤缓解情况数据截止时，研究共报告123例死亡事件，其中哌柏西利联合H±P+ET组60例、H±P+ET组63例。OS目前尚不成熟，需达到247个死亡事件后再予分析。哌柏西利联合H±P+ET组5年OS率较H±P+ET组呈改善趋势（74.3% vs 69.8%），死亡风险降低14%（HR=0.86, 95%CI, 0.61-1.23）。上述结果表明，在HR+/HER2+晚期乳腺癌一线维持抗HER2治疗联合ET治疗的基础上，加用CDK4/6抑制剂可进一步提升整体治疗效果，为延长患者生存奠定了基础。 PATINA研究OS结果规范管理安全性保障患者生活质量晚期乳腺癌的治疗目的是在保证患者生活质量的基础上，控制肿瘤、减轻症状、延长生存[13]。PATINA研究在HR+/HER2+晚期乳腺癌一线维持治疗的基础上引入CDK4/6抑制剂哌柏西利，在安全性管理方面也带来了新的挑战。安全性结果显示，哌柏西利联合H±P+ET组与H±P+ET组相比，任意级别不良事件发生率相当，均为94.4%；但≥3级不良事件的发生率显著升高，分别为79.7% vs. 30.6%，其中以中性粒细胞减少 (60.5% vs 2.0%) 和白细胞减少 (16.1% vs 0.8%)最为常见。中性粒细胞减少也是该研究中导致剂量降低的最常见不良事件。此外，哌柏西利联合H±P+ET组在乏力、腹泻、口腔炎等不良事件的发生率也高于对照组，临床实践中需要加强相关不良反应的管理。 PATINA研究不良反应事件在生活质量方面，研究者采用FACT-B和EQ-5D-5L量表予以评估，各组HRQOL从基线到治疗结束均保持稳定，各时间点的整体生活质量和功能量表评分均无显著差异。尽管加用CDK4/6抑制剂增加了不良反应，但未对患者整体生活质量造成不良影响，提示哌柏西利联合H±P+ET方案一线维持治疗HR+/HER2+乳腺癌具有良好的临床获益-风险平衡。 PATINA研究生活质量综上所述，PATINA研究表明对于HR+/HER2+晚期乳腺癌患者，在一线抗HER2靶向治疗联合ET维持治疗的基础上加用CDK4/6抑制剂，可显著延长患者PFS，且未影响生活质量。该方案整体获益明确，临床应用时注意管理中性粒细胞减少等不良反应，以保障治疗依从性，最大化临床获益。大咖点评陈文艳教授南昌市人民医院 HR+/HER2+乳腺癌临床特征表现为生物学活跃程度高、肿块大、Ki-67指数高，具有高度增殖与更强侵袭性，是临床治疗的一大难题。传统的单纯抗HER2治疗策略疗效相对有限，CLEOPATRA研究中HR+/HER2+患者占28%，一线应用HP双靶联合化疗相较对照组降低了28%的疾病进展或死亡风险，而HR-/HER2+人群中这一数值为55%[14]。与之类似，PHILA研究中曲妥珠单抗联合TKI与化疗一线治疗HR+/HER2+人群的风险降低幅度也小于HR-/HER2+人群[15]。究其机制，是因为HR信号通路与HER2信号通路之间存在串扰，单纯阻断任一通路均难以发挥持久的抗肿瘤效果。虽然抗HER2靶向治疗联合化疗诱导治疗后序贯抗HER2联合ET维持逐渐成为HR+/HER2+晚期乳腺癌的治疗选择，但SYSUCC-002研究显示，曲妥珠单抗联合化疗与曲妥珠单抗联合ET的mOS分别为33.9个月和32.5个月，生存获益无显著差异[16]。在此背景下，PATINA研究则为一线维持治疗带来了全新的选择，在传统抗HER2联合ET治疗的基础上加用CDK4/6抑制剂，可将中位PFS提升至44.3个月，较对照组延长1年以上，刷新了该人群的疗效记录。这一显著疗效验证了CDK4/6与HER2双重抑制的协同效应，为治疗策略的优化提供了新思路。在该研究的推动下，美国NCCN指南[17]及中国乳腺癌指南[18]均已将“H±P+ET±CDK4/6抑制剂”纳入HR+/HER2+一线治疗范畴。值得关注的是，PATINA研究引入CDK4/6抑制剂后，中性粒细胞减少发生率显著升高，≥3级达60.5%（对照组为2.0%）。该研究72.3%的剂量降低事件由中性粒细胞减少所致，提示临床实践中需重视其规范化管理，或考虑采用骨髓抑制发生率更低的替代方案。从机制上看，乳腺癌细胞G1期进展主要由CDK4驱动，而CDK6则主要表达于骨髓细胞。传统CDK4/6抑制剂对CDK4和CDK6的同步抑制，是导致血液毒性的关键原因。我国自主研发的新型CDK2/4/6抑制剂库莫西利，在保持高选择性抑制CDK4的基础上，降低了对CDK6的抑制，同时增加了对CDK2的抑制作用，从而在保留核心抗肿瘤机制的同时，有望降低骨髓抑制并延缓耐药发生[19]。目前库莫西利已在内分泌经治的HR+/HER2-晚期乳腺癌中获批应用，其III期CULMINATE-1研究显示在内分泌经治的HR+/HER2-晚期乳腺癌中，库莫西利的mPFS达到16.6个月（对照组为7.5个月），而≥3级中性粒细胞减少的发生率仅为24.74%，显著降低了靶向CDK治疗药物的血液毒性[20]。同时，其在HR+/HER2-晚期乳腺癌一线治疗的Ⅲ期CULMINATE-2研究也显示，库莫西利组研究者评估的中位PFS尚未达到（对照组为20.2个月），≥3级中性粒细胞减少的发生率进一步降至20.3%，与其机制优势相契合[21]。在HR+/HER2+晚期乳腺癌中，PATINA研究的阳性结果验证了同步抑制HER2和CDK4/6的协同作用。展望未来，这一模式或可进一步拓展，探索以更低血液毒性、更强抗肿瘤活性的CDK2/4/6抑制剂替代传统CDK4/6抑制剂的可行性，为我国HR+/HER2+乳腺癌患者提供更高效、更低毒的治疗选择。总之，HR+/HER2+晚期乳腺癌的治疗策略始终朝着延长患者生存、改善生活质量的方向不断演进。PATINA研究为这一领域的临床实践提供了重要循证依据，也为后续更精准、更温和的治疗方案探索奠定了坚实基础。参考文献上下滑动查看更多内容 [1] Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. Published 2014 Apr 28. doi:10.1093/jnci/dju055 [2] Zhao S, Liu XY, Jin X, et al. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. Theranostics. 2019;9(17):4935-4945. Published 2019 Jul 9. doi:10.7150/thno.35730 [3] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) for breast cancer, version 5.2025. [4] Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. doi:10.1016/j.breast.2024.103756 [5] Otto Metzger, et al. AFT-38 PATINA A Randomized, Open-Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer. 2024 SABCS. [6] I.V. Vaz-Luis, G. Mazza, et al. Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC). Annals of Oncology, 36S378. 2025 ESMO 485MO. [7] Metzger O, Mandrekar S, Goel S, et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. N Engl J Med. 2026;394(5):451-462. doi:10.1056/NEJMoa2511218 [8] Xie J, Yang Z, Li Z, et al. Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes. Cancer Cell Int. 2025;25(1):77. Published 2025 Mar 5. doi:10.1186/s12935-025-03680-7 [9] Goel S, Wang Q, Watt AC, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016;29(3):255-269. doi:10.1016/j.ccell.2016.02.006 [10] Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol 2018; 19: 249-56. [11] Ciruelos E, Villagrasa P, Pascual T, et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial. Clin Cancer Res 2020; 26: 5820-9. [12]Malorni L, Tyekucheva S, Zamagni C, et al. Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neo-adjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). Clin Cancer Res 2025; 31: Suppl 12: RF1-02. [13] 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南（2024版）[J]. 中华肿瘤杂志, 2024, 46(12): 1079-1106. DOI: 10.3760/cma.j.cn112152-20241009-00435. [14] Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119. doi:10.1056/NEJMoa1113216 [15] Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065. Published 2023 Oct 31. doi:10.1136/bmj-2023-076065 [16] Hua X, Bi XW, Zhao JL, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022;28(4):637-645. doi:10.1158/1078-0432.CCR-21-3435 [17] NCCN Guidelines 2026.v2 Invasive Breast Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [18] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会和中华医学会肿瘤学分会乳腺癌诊治指南与规范（2026版精要本）. 2025.12.20. [19] Zhaobing Xu, Yingchun Liu, Baohui Song, et al. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor[J]. Bioorganic & Medicinal Chemistry Letters, 2024, 107: 129769. [20] Yin Y, Zhang Q, Sun T, et al. Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2025 Dec 18;10(1):414. [21] Erwei. Song, Yinyong. Yin, Jianli. Zhao, et al. Culmerciclib Plus Fulvestrant as First-Line Treatment for HR+/HER2- Advanced Breast Cancer: A Phase 3 Trial (CULMINATE-2) .ESMO 2025：LBA25. 往期推荐 1 BC TALK丨陶思丰教授：HR+/HER2-晚期乳腺癌患者，CDK4/6抑制剂越早使用越好吗？ 2 BC TALK丨陈占红教授：Bridging the Gap——HER2阳性晚期乳腺癌一线治疗的“弥合”之道陈文艳教授南昌市人民医院乳腺内科科主任中国临床肿瘤学会乳腺癌专委会委员中国抗癌协会乳腺癌专业委员会委员中国抗癌协会乳腺肿瘤整合康复专委会常委长江学术带乳腺联盟副主委中国医药教育协会乳腺疾病规范化诊治江西培训基地候任主委江西抗癌协会乳腺癌专委会青委会主委中国医药教育协会乳腺疾病专委会乳腺癌多学科诊疗学组副主委江西省研究型医院学会乳腺肿瘤分会副主委（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-04-01

·ioncology

2026 SGO全体大会精粹：妇科肿瘤关键临床试验与治疗策略更新

2026年美国妇科肿瘤学会（SGO）年会将于4月10-13日在波多黎各圣胡安举行。作为全球妇科肿瘤领域的顶级学术盛会，本届年会在Exhibit Hall A举办五场全体大会（Scientific Plenary），集中展示了从靶向治疗、免疫疗法到手术革新和遗传学管理的最新进展。以下是各场全体大会的核心内容介绍。全体大会 I：Advancing Science through Clinical Trials（通过临床试验推进科学）时间：2026年4月10日（周五）4:45 PM - 5:45 PM AST 主持专家：Pamela Soliman, MD；Christine Walsh, MD 英文标题：Final Overall Survival (OS) Results From the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) 中文标题：III期ROSELLA试验的最终总生存期结果：Relacorilant联合白蛋白紫杉醇对比白蛋白紫杉醇单药治疗铂耐药卵巢癌患者（GOG-3073、ENGOT-ov72、APGOT-Ov10、LACOG-0223）讲者：Alexander Olawaiye, MD 英文标题：Encore: Pembrolizumab vs Placebo Plus Weekly Paclitaxel ± Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Final Analysis Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study 中文标题：再现：帕博利珠单抗对比安慰剂联合周疗紫杉醇±贝伐珠单抗治疗铂耐药复发性卵巢癌——随机双盲III期ENGOT-ov65/KEYNOTE-B96研究最终分析结果讲者：Bradley Monk, MD 英文标题：Long-Term Efficacy and Safety of Avutometinib + Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201 中文标题：Avutometinib+Defactinib治疗复发性低级别浆液性卵巢癌的长期疗效与安全性：ENGOT-OV60/GOG-3052/RAMP 201研究结果讲者：Rachel Grisham, MD 英文标题：GOG-3039: A Phase II Trial of Abemaciclib Plus Letrozole in Recurrent or Persistent Endometrioid Endometrial Carcinoma (NCT04393285) 中文标题：GOG-3039：阿贝西利联合来曲唑治疗复发或持续性子宫内膜样子宫内膜癌的II期试验（NCT04393285）讲者：Marilyn Huang, MD, MS, FACOG 英文标题：Results of a Randomized Phase III Trial of Letrozole Alone Versus Paclitaxel and Carboplatin Followed by Letrozole as Initial Treatment for Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Low-Grade Serous Carcinoma (NRG-GY019, NCT04095364) 中文标题：来曲唑单药对比紫杉醇+卡铂序贯来曲唑作为II-IV期卵巢、输卵管或原发性腹膜低级别浆液性癌初始治疗的随机III期试验结果（NRG-GY019，NCT04095364）讲者：Amanda Fader, MD 总结与点评（Distillation）点评专家：Roisin O'Cearbhaill, MD 全体大会 II：Transforming Endometrial Cancer Care（变革子宫内膜癌治疗）时间：2026年4月11日（周六）8:45 AM - 9:30 AM AST 主持专家：Eloise Chapman-Davis, MD；Rebecca Arend, MD, MPH 英文标题：Trastuzumab Pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical Phase 2 data 中文标题：DB-1303用于经治的HER2表达晚期/转移性子宫内膜癌患者：首次全球临床II期数据讲者：Bhavana Pothuri, MD, MS 英文标题：Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for recurrent/advanced endometrial carcinoma: a multi-center, single-arm phase II clinical trial 中文标题：卡度尼利单抗联合化疗一线治疗复发/晚期子宫内膜癌的疗效与安全性：一项多中心、单臂II期临床试验讲者：Yang Sun, MD 英文标题：The social interventions for support in treatment of endometrial cancer and recurrence (SISTER) study: A national randomized controlled trial of peer support vs. usual care in Black women with high-risk endometrial cancer 中文标题：子宫内膜癌及复发治疗中的社会支持干预（SISTER）研究：一项针对高危子宫内膜癌黑人女性的全国性同伴支持对比常规护理的随机对照试验讲者：Kemi Doll, MD, MSCR 英文标题：Facilitated Genetic Cascade Testing (FaCT): A Prospective Multi-Institutional Randomized Controlled Trial 中文标题：促进式遗传级联检测（FaCT）：一项前瞻性多机构随机对照试验讲者：Roni Nitecki Wilke, MD, MPH 总结与点评（Distillation）点评专家：Bradley Corr, MD 全体大会 III：Surgical Showdown - Farr Nezhat Session（外科对决——Farr Nezhat专场）时间：2026年4月11日（周六）11:35 AM - 12:35 PM AST 主持专家：Nicole Fleming, MD；John Moroney, MD 英文标题：Introduction and Announcement of Surgical Film Winner 中文标题：专场介绍，外科手术影片获奖者公布讲者：Farr Nezhat, MD, FACOG, FACS 英文标题：Renal Vein Angle and Standardized Technique for Single-Port Laparoscopic Paraaortic Lymphadenectomy 中文标题：基于肾静脉角度的单孔腹腔镜腹主动脉旁淋巴结清扫标准化技术讲者：Hua Tu, MD 英文标题：Laparoscopic Uterine & Ovarian Transposition with Oophoropexy and Cervical Stoma Creation 中文标题：腹腔镜子宫卵巢移位、固定及宫颈造口术讲者：Robert DeBernardo, MD 总结与点评（Distillation）点评专家：Emma Rossi, MD 英文标题：Debate - Primary Cytoreductive Surgery (PCS) 中文标题：辩论——初次肿瘤细胞减灭术讲者：Carrie Langstraat, MD 英文标题：Debate - Neoadjuvant Chemotherapy (NACT) 中文标题：辩论——新辅助化疗讲者：Jason Wright, MD 全体大会 IV：Innovate to Eliminate - New Therapeutics（创新以消除妇瘤——新疗法）时间：2026年4月12日（周日）10:00 AM - 11:00 AM AST 主持专家：Edwin Alvarez, MD；John Hays, MD, PhD 英文标题：Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study 中文标题：Mocertatug rezetecan（GSK5733584），一种靶向B7-H4的抗体药物偶联物，治疗铂耐药卵巢癌和子宫内膜癌：全球BEHOLD-1研究的首次结果讲者：Ana Oaknin, MD, PhD 英文标题：SYS6043, a B7-H3 targeting antibody-drug conjugates in patients with advanced gynecologic cancers: a phase 1/2, first-in-human study 中文标题：靶向B7-H3的抗体药物偶联物SYS6043用于晚期妇科癌症患者：一项I/II期首次人体研究讲者：Jing Zuo, MD 英文标题：Updated results from the first-in-human phase 1 study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha (FRα) in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC) 中文标题：靶向叶酸受体α的抗体药物偶联物LY4170156治疗复发铂耐药高级别浆液性卵巢癌的首次人体1期研究更新结果讲者：Bhavana Pothuri, MD, MS 英文标题：The pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer 中文标题：评估选择性p53再激活剂rezatapopt治疗携带TP53 Y220C突变的晚期或转移性实体瘤患者的关键性PYNNACLE II期试验：卵巢癌患者的中期分析讲者：Alison Schram, MD 英文标题：Phase II Study of Camrelizumab plus Apatinib Combined with Chemotherapy in High-Risk, Chemoresistant Gestational Trophoblastic Neoplasia 中文标题：卡瑞利珠单抗联合阿帕替尼及化疗治疗高危、耐药性妊娠滋养细胞肿瘤的II期研究讲者：蒋芳教授总结与点评（Distillation）点评专家：Stephanie Gaillard, MD, PhD 全体大会 V：Emerging Strategies in Cervical Cancer Care（宫颈癌治疗的新兴策略）时间：2026年4月13日（周一）11:15 AM - 12:15 PM AST 主持专家：Charles Leath, III, MD, MSPH；Roberto Vargas, MD 英文标题：Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab in Participants With Recurrent or Metastatic Cervical Cancer: Results From the Phase 2 2870-002/SKB264-II-06 Study 中文标题：Sac-TMT联合帕博利珠单抗治疗复发或转移性宫颈癌：II期2870-002/SKB264-II-06研究结果讲者：吴小华教授英文标题：Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study 中文标题：Tisotumab vedotin联合卡铂和帕博利珠单抗±贝伐珠单抗一线治疗复发或转移性宫颈癌：ENGOT-cx8/GOG-3024/innovaTV 205研究中H组的首次数据公布讲者：Toon Van Gorp, MD, PhD 英文标题：Development of ENG–Targeted CAR T cells for cervical cancer: Direct tumor targeting and microenvironment modulation 中文标题：靶向ENG的CAR-T细胞治疗宫颈癌的开发：直接靶向肿瘤与微环境调控讲者：Min Guan, MD, PhD 英文标题：Exclusion of Individuals with HIV from Cervical Cancer Clinical Trials: Lack of Progress in the Immunotherapy Era 中文标题：宫颈癌临床试验中HIV感染者的排除问题：免疫治疗时代进展寥寥讲者：Lauren Gottshall, MD 总结与点评（Distillation）点评专家：Ritu Salani, MD, MBA （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期免疫疗法临床2期临床结果

2026-04-01

·新浪看点

悦康药业涨11.50%，成交额4.65亿元，近3日主力净流入1976.96万

4月1日，悦康药业涨11.50%，成交额4.65亿元，换手率5.53%，总市值85.95亿元。异动分析细胞免疫治疗+创新药+幽门螺杆菌概念+仿制药一致性评价+人工智能1、根据2025年3月15日公告：公司有自主研发的细胞与基因治疗药物开发平台，本平台具备先进的CAR设计技术，运用CRISPR/C as9基因编辑实现精准改造。通过实体瘤靶点筛选及双靶点CAR结构创新，开发双靶点CAR-T、CAR-NK 疗法。利用FASTCART平台技术降低成本、缩短制备周期，借助流式细胞术保证细胞筛选和质量。同时，结合mRNA-LNP 技术前瞻性布局in vivo细胞疗法。2、根据2025年3月15日公告：各项创新药研发进程加速推进的同时，公司在研发领域也取得了重大突破性成果。如：重点研发项目——靶向PCSK9的siRNA 1.1类创新药YKYY015注射液，成功获得了发明专利授权。这一里程碑式的成就，不仅彰显了公司在创新药物研发方面的雄厚实力和卓越能力，也为后续的临床试验和市场推广奠定了坚实基础。3、公司拟投资 10,000.00 万元建设新的原料药生产线。项目建成后，达产年生产能力为双氯芬酸钠年产 330 吨、兰索拉唑年产 10吨，来曲唑年产 0.30 吨。兰索拉唑为一种新型抑制胃酸分泌药物，对幽门螺杆菌的抑菌活性比奥美拉唑较高。4、2024年2月6日互动易回复，截止2024年1月，公司共15项产品已通过仿制药一致性评价。5、2023年年报：在人工智能药物开发方面，公司搭建了多个AI深度学习模型，可用于靶标发现、药物设计、药物筛选、化学合成、工艺开发及参数优化等全链条药物研发环节。用于多肽、阳离子脂质、肿瘤新抗原等药物的全新设计，以及药物活性和毒性筛选，并已向国家知识产权局提交4项AI药物算法专利。公司借助已开发的AI算法模型可以实现药物的从头设计，已设计出多个候选分子并正在系统地进行实验验证，这将高效地缩短药物设计和筛选进程，提升药物研发的效率。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入2784.30万，占比0.06%，行业排名37/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入35.15亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入2784.30万1976.96万2437.19万-175.05万219.32万主力持仓主力没有控盘，筹码分布非常分散，主力成交额4870.29万，占总成交额的6.46%。技术面：筹码平均交易成本为22.05元该股筹码平均交易成本为22.05元，近期该股获筹码青睐，且集中度渐增；目前股价在压力位19.70和支撑位17.83之间，可以做区间波段。公司简介资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类43.42%，抗感染类24.10%，原料药8.67%，消化系统类8.58%，其他7.54%，降糖类7.35%，其他(补充)0.26%，技术服务0.09%。悦康药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI应用（医药医疗）、中药、医药电商、创新药、人工智能等。截至2月28日，悦康药业股东户数1.30万，较上期增加34.33%；人均流通股34564股，较上期减少25.55%。2025年1月-12月，悦康药业实现营业收入24.46亿元，同比减少35.30%；归母净利润-2.62亿元，同比减少312.09%。分红方面，悦康药业A股上市后累计派现10.92亿元。近三年，累计派现5.84亿元。机构持仓方面，截止2025年12月31日，悦康药业十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第六大流通股东，持股1077.41万股，持股数量较上期不变。富国医药创新股票A（019916）位居第八大流通股东，持股792.23万股，相比上期增加109.01万股。易方达医疗保健行业混合A（110023）位居第九大流通股东，持股767.07万股，相比上期减少209.58万股。富国天博创新混合（519035）退出十大流通股东之列。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。

细胞疗法免疫疗法一致性评价

100 项与来曲唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00964	来曲唑	L02BG04	DB01006

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
不孕	日本	Novartis Pharma AG	2022-02-25
转移性乳腺癌	美国	Novartis Pharmaceuticals Corp.	1997-07-25
乳腺癌	瑞典	Novartis AG	1996-12-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢子宫内膜样癌	临床3期	奥地利	Hoffmann-La Roche, Inc.	2020-11-05
卵巢子宫内膜样癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2020-11-05
卵巢子宫内膜样癌	临床3期	德国	Novartis Pharmaceuticals Corp.	2020-11-05
卵巢子宫内膜样癌	临床3期	德国	Hoffmann-La Roche, Inc.	2020-11-05
卵巢子宫内膜样癌	临床3期	瑞士	Novartis Pharmaceuticals Corp.	2020-11-05
卵巢子宫内膜样癌	临床3期	瑞士	Hoffmann-La Roche, Inc.	2020-11-05
输卵管癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2020-11-05
输卵管癌	临床3期	奥地利	Hoffmann-La Roche, Inc.	2020-11-05
输卵管癌	临床3期	德国	Novartis Pharmaceuticals Corp.	2020-11-05
输卵管癌	临床3期	德国	Hoffmann-La Roche, Inc.	2020-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03747042 (CTgov)	临床2期	乳腺癌	61	Letrozole	築憲餘選餘窪糧憲淵膚 = 衊廠鑰鏇糧餘窪築築願鏇憲鬱鏇積構醖淵艱膚 (製齋遞範網觸廠膚糧壓, 衊夢遞簾範鹹構窪網構 ~ 鏇餘構選夢顧鏇鏇憲憲) 更多	-	2026-03-16
NCT03879577 (ARETTA, CTgov)	临床2期	HER2阳性乳腺癌	53	Herceptin+LHRH agonist+Tamoxifen+Letrozole+Docetaxel	選襯衊鹽獵鹽簾膚積夢 = 獵鬱遞廠壓蓋獵膚艱鹽鹽遞鑰餘糧衊願網構顧 (顧顧艱鹹積壓觸夢鑰鹽, 觸窪夢獵製襯蓋鹹壓膚 ~ 夢積夢蓋壓鹽繭艱壓壓) 更多	-	2026-01-21
NCT03673124 (CTgov)	临床2期	复发性低级别输卵管浆液性腺癌 \| 卵巢癌 \| 浆液性囊腺癌	51	Letrozole+Ribociclib	繭艱鹽遞餘鬱廠遞觸製 = 簾築積鑰鏇鏇範築繭觸製窪獵膚鬱鬱構顧簾獵 (鬱衊鹽夢膚衊餘夢鏇簾, 鹽繭齋夢製觸簾積顧願 ~ 齋齋積願淵積襯遞鏇選) 更多	-	2025-12-23
NCT05601700 (Pubmed \| Tumori)	临床3期	HR阳性卵巢癌 ER/PgR-positive	46	Letrozole 2.5 mg	願夢選壓蓋糧鹹積顧糧(膚憲淵築網壓網艱鹹積) = 壓範範鬱廠構艱獵醖築糧膚憲齋範衊願鏇壓糧 (獵膚積獵願糧艱構醖顧, 51.1 ~ 84.4)	积极	2025-12-14
NCT07014410 (SYSUCC-002, SABCS2025)	临床2期	HER2阳性转移性乳腺癌一线 HER2-Positive \| Estrogen Receptor-Positive	16	PyrotinibDalpiciclibLetrozoleib + PyrotinibDalpiciclibLetrozole + PyrotinibDalpiciclibLetrozole (Estrogen Receptor-Positive and HER2-Positive Metastatic Breast Cancer)	膚憲蓋衊艱願膚鬱襯遞(觸鬱醖簾膚積餘鏇遞憲) = 夢鏇鬱鹽餘觸蓋鬱積構構鹽窪範夢鏇鑰淵糧鏇 (觸艱願壓壓餘築齋餘憲, 41 ~ 88)	积极	2025-12-12
NCT04735367 (Pubmed \| Breast Cancer)	临床2期	ER阳性/HER2阴性乳腺癌一线 ER+/HER2−	42	Palbociclib plus letrozole	鑰糧壓廠蓋繭餘製積憲(積選築繭範鹹鬱製網積) = 艱糧蓋製觸範憲鏇築廠窪觸簾襯夢選醖製糧顧 (網鑰獵廠膚廠壓廠艱製, 64.3 ~ NE) 更多	积极	2025-11-01
NCT04272801 (POWER, CTgov)	临床2期	早期乳腺癌	84	Patient reported outcomes+letrozole+tamoxifen+exemestane+anastrozole	淵襯鹽積鑰蓋願簾鹹齋 = 衊觸窪衊顧衊襯衊蓋繭醖蓋壓範夢築構鹽窪觸 (蓋網積獵構製鬱憲鏇顧, 窪範鏇鏇範糧鹹夢襯觸 ~ 積艱餘餘鹽積膚獵遞鏇) 更多	-	2025-10-22
ESMO2025	N/A	HR阳性/HER2阴性乳腺癌一线 HR+/HER2-	1,267	Letrozole plus Palbociclib	繭蓋鬱廠繭艱齋艱膚鬱(繭夢鏇鬱遞網鑰廠鑰淵): HR = 0.59 (95.0% CI, 0.51 ~ 0.69) 更多	积极	2025-10-17
ESMO2025	N/A	HR阳性/HER2阴性乳腺癌一线 HR+/HER2-	1,267	Letrozole plus Placebo		积极	2025-10-17
NCT04486911 (MUKDEN 01, ESMO2025)	临床2期	ER阳性/PR阳性/HER2阳性乳腺癌一线 \| 新辅助 ER Positive \| PR Positive \| HER2 Positive	81	Pyrotinib+Letrozole+Dalpiciclib	鏇膚網顧糧淵淵鹽壓衊(憲蓋願壓簾膚醖觸鏇鹽) = 憲糧鹹築廠獵構齋淵窪鏇遞製鑰窪鏇遞鑰憲憲 (齋範鏇繭膚顧廠襯構淵, 88.6 ~ 99.1) 更多	积极	2025-10-17
NCT00001521 (CTgov)	临床3期	先天性肾上腺增生 \| 21-羟化酶缺乏症引起的先天性肾上腺皮质增生	66	Fludrocortisone+Letrozole+Testolactone+Flutamide+Hydrocortisone (Investigational Therapy)	窪範夢獵構觸網製積範(夢夢齋觸鏇蓋顧願願糧) = 醖願製鬱夢艱獵鹹築鹽願淵網鑰膚積製醖範齋 (蓋窪製壓鑰鏇餘艱獵膚, 0.93) 更多	-	2025-06-12
NCT00001521 (CTgov)	临床3期	先天性肾上腺增生 \| 21-羟化酶缺乏症引起的先天性肾上腺皮质增生	66	Fludrocortisone+Hydrocortisone (Standard Therapy)	窪範夢獵構觸網製積範(夢夢齋觸鏇蓋顧願願糧) = 餘繭鏇網積餘築衊醖蓋願淵網鑰膚積製醖範齋 (蓋窪製壓鑰鏇餘艱獵膚, 0.89) 更多	-	2025-06-12